133 related articles for article (PubMed ID: 20167563)
1. [Mechanisms of resistance to molecular targeted therapies in breast cancer: update and future].
Magné N; Chargari C; Conforti R; Toillon RA; Bauduceau O; Védrine L; Khayat D; Spano JP
Bull Cancer; 2010 Mar; 97(3):385-95. PubMed ID: 20167563
[TBL] [Abstract][Full Text] [Related]
2. Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway.
Nahta R; O'Regan RM
Clin Breast Cancer; 2010 Nov; 10 Suppl 3():S72-8. PubMed ID: 21115425
[TBL] [Abstract][Full Text] [Related]
3. Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer.
Orlando L; Cardillo A; Ghisini R; Rocca A; Balduzzi A; Torrisi R; Peruzzotti G; Goldhirsch A; Pietri E; Colleoni M
BMC Cancer; 2006 Sep; 6():225. PubMed ID: 16978400
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells.
Vazquez-Martin A; Colomer R; Brunet J; Menendez JA
Int J Oncol; 2007 Oct; 31(4):769-76. PubMed ID: 17786307
[TBL] [Abstract][Full Text] [Related]
5. Her2-positive breast cancer: herceptin and beyond.
Dean-Colomb W; Esteva FJ
Eur J Cancer; 2008 Dec; 44(18):2806-12. PubMed ID: 19022660
[TBL] [Abstract][Full Text] [Related]
6. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer.
Spector NL; Blackwell KL
J Clin Oncol; 2009 Dec; 27(34):5838-47. PubMed ID: 19884552
[TBL] [Abstract][Full Text] [Related]
7. Trastuzumab: targeted therapy for the management of HER-2/neu-overexpressing metastatic breast cancer.
Emens LA
Am J Ther; 2005; 12(3):243-53. PubMed ID: 15891269
[TBL] [Abstract][Full Text] [Related]
8. Overcoming resistance against HER2-targeting agents in fifth-line therapy: is there still a place for bevacizumab in HER2+ breast cancer?
Huemer F; Gampenrieder SP; Schlattau A; Greil R
Clin Breast Cancer; 2014 Feb; 14(1):e17-20. PubMed ID: 24246725
[No Abstract] [Full Text] [Related]
9. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer.
Nahta R; Yu D; Hung MC; Hortobagyi GN; Esteva FJ
Nat Clin Pract Oncol; 2006 May; 3(5):269-80. PubMed ID: 16683005
[TBL] [Abstract][Full Text] [Related]
10. Novel cytotoxic backbones and targeted therapies: recent data and ongoing clinical trials.
Moulder SL
Clin Breast Cancer; 2010 Sep; 10 Suppl 2():S30-40. PubMed ID: 20805063
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of HER2-targeted therapy in metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors.
Nielsen DL; Kümler I; Palshof JA; Andersson M
Breast; 2013 Feb; 22(1):1-12. PubMed ID: 23084121
[TBL] [Abstract][Full Text] [Related]
12. Integration of novel targeted therapies into the systemic treatment of breast cancer--a review.
Tsakonas G; Kosmas C
J BUON; 2007; 12(3):319-27. PubMed ID: 17918284
[TBL] [Abstract][Full Text] [Related]
13. Blockade of the HER family of receptors in the treatment of HER2-positive metastatic breast cancer.
Sachdev JC; Jahanzeb M
Clin Breast Cancer; 2012 Feb; 12(1):19-29. PubMed ID: 21903480
[TBL] [Abstract][Full Text] [Related]
14. Resistance to HER2 inhibitors: is addition better than substitution? Rationale for the hypothetical concept of drug sedimentation.
Campone M; Juin P; André F; Bachelot T
Crit Rev Oncol Hematol; 2011 Jun; 78(3):195-205. PubMed ID: 20684884
[TBL] [Abstract][Full Text] [Related]
15. Trastuzumab and beyond: New possibilities for the treatment of HER2-positive breast cancer.
Morris SR; Carey LA
Oncology (Williston Park); 2006 Dec; 20(14):1763-71; discussion 1771-2, 1774-6. PubMed ID: 17263127
[TBL] [Abstract][Full Text] [Related]
16. Information for patients. HER2+ early breast cancer: understanding adjuvant treatment.
Helwick C
Oncology (Williston Park); 2009 Oct; 23(11 Suppl Nurse Ed):8a-8b. PubMed ID: 19856601
[No Abstract] [Full Text] [Related]
17. Breast tumour angiogenesis.
Fox SB; Generali DG; Harris AL
Breast Cancer Res; 2007; 9(6):216. PubMed ID: 18190723
[TBL] [Abstract][Full Text] [Related]
18. HER2 as a target for breast cancer therapy.
Tagliabue E; Balsari A; Campiglio M; Pupa SM
Expert Opin Biol Ther; 2010 May; 10(5):711-24. PubMed ID: 20214497
[TBL] [Abstract][Full Text] [Related]
19. Bevacizumab in the treatment of breast cancer.
Koutras AK; Fountzilas G; Makatsoris T; Peroukides S; Kalofonos HP
Cancer Treat Rev; 2010 Feb; 36(1):75-82. PubMed ID: 19932567
[TBL] [Abstract][Full Text] [Related]
20. Strategies for delaying or treating in vivo acquired resistance to trastuzumab in human breast cancer xenografts.
du Manoir JM; Francia G; Man S; Mossoba M; Medin JA; Viloria-Petit A; Hicklin DJ; Emmenegger U; Kerbel RS
Clin Cancer Res; 2006 Feb; 12(3 Pt 1):904-16. PubMed ID: 16467105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
